ImmuPharma PLC has spotlighted early-stage research from the University of Murcia exploring its lead drug candidate, the P140 peptide, as a possible treatment for glioblastoma, a highly aggressive brain cancer. While the company primarily focuses on developing P140 for autoimmune diseases, this new research suggests an additional application for the drug. ImmuPharma has been monitoring this research since 2024 and remains committed to advancing P140 as its lead asset. The glioblastoma findings support the company's broader scientific rationale but do not change its core strategy.
Bitcoin surged above $63,000 as US political and regulatory developments, including a Senate probe linked to President Trump's family and upcoming crypto tax legislation, influenced market sentiment. Meanwhile, China advanced legal clarity on its dig...
Solana (SOL) has fallen 5-7% to trade around $68-69 after a large whale initiated a 20x leveraged short position worth approximately $38 million near $69. This bearish move pressures the market as SOL struggles to reclaim the $70 level, with critical...
Buccaneer Energy reported an 18% increase in its proved oil reserves following an independent review linked to its bank credit facility with WAFD Bank. The company’s forecast cash flow rose 27%, boosting the net present value of reserves to $11.8 mil...
XRP's price dropped about 10% over the past week and 20% monthly, pressured by a broader crypto market decline triggered by Bitcoin falling below $65,000. Despite continuous accumulation by XRP-focused spot ETFs for seven weeks and a new conditional ...
Worldline has become the first payment provider in Europe to enable Click to Pay for recurring payments, enhancing the subscription payment experience for international merchants. This one-click checkout solution reduces friction, increases payment s...
